APHRIA INC.

APHA

Delayed - 01/15 04:15:02 pm
15.82CAD	+3.74%

04/19/21	Q3 2021 Earnings Release (Projected)
08/04/21	FY 2021 Earnings Release (Projected)
10/20/21	Q1 2022 Earnings Release (Projected)
01/13/22	Interim 2022 Earnings Release (Projected)

01/14/21 \| 09:00am	Interim 2021 Earnings Call
01/14/21 \| 07:13am	Interim 2021 Earnings Release
12/16/20 \| 08:30am	Aphria and Tilray Merger Call
11/17/20 \| 10:00pm	Annual General Meeting

01/17/21 \| 03:30pm	ROCHE HOLDING AG : Gastrointestinal Cancers Symposium
01/19/21	BRIDGEBIO PHARMA, INC. : Extraordinary Shareholders Meeting - M&A Vote
01/22/21 \| 02:30am	BETTA PHARMACEUTICALS CO., LTD. : Extraordinary Shareholders Meeting
01/22/21 \| 01:00am	WALVAX BIOTECHNOLOGY CO., LTD. : Extraordinary Shareholders Meeting

01/15/21	EISAI CO., LTD. : American society of clinical oncology virtual gastrointestinal cancers symposium - abstract #: 94
01/15/21	EISAI CO., LTD. : American society of clinical oncology virtual gastrointestinal cancers symposium - abstract #: 298
01/15/21	EISAI CO., LTD. : American society of clinical oncology virtual gastrointestinal cancers symposium - abstract #: 321
01/15/21	EISAI CO., LTD. : American society of clinical oncology virtual gastrointestinal cancers symposium - abstract #: 273

Previous year

Next Year

Annual results		2016	2017	2018	2019	2020	2021 (e)
Sales M CAD	Released Forecast Spread	8,43 8,70 -3,1%	20,4 20,1 1,5%	36,9 36,5 1,2%	237 211 12%	543 542 0,18%	686
Operating income (EBITDA) M CAD	Released Forecast Spread	0,57	6,08 4,14 47%	8,42 8,91 -5,5%	-27,7 -42,6 35%	17,2 16,6 4,1%	62,3
Operating profit (EBIT) M CAD	Released Forecast Spread	-1,09	0,66	-12,4 -12,7 2,0%	-145 -128 -13%	-66,1 -22,6 -193%	-21,0
Pre-Tax Profit (EBT) M CAD	Released Forecast Spread	-0,80	4,33 7,00 -38%	35,9 37,6 -4,5%	-15,6 -96,4 84%	-80,7 8,80 -1 017%	-115
Net income M CAD	Released Forecast Spread	0,40	4,20 6,87 -39%	29,4 31,2 -5,5%	-16,5 -51,4 68%	-84,6 4,62 -1 931%	-135
EPS CAD	Released Forecast Spread	0,01 -0,01 200%	0,04 0,06 -36%	0,18 0,19 -4,3%	-0,07 -0,20 65%	-0,33 -0,03 -942%	-0,50
Announcement Date		07/08/2016	07/12/2017	08/01/2018	08/01/2019	07/29/2020

Previous period

Next period

Quarterly results		2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3 (e)	2021 Q4 (e)	2022 Q1 (e)	2022 Q2 (e)	2022 Q3 (e)
Sales M CAD	Released Forecast Spread	13,3 13,4 -1,1%	21,7 23,7 -8,7%	73,6 83,5 -12%	129 102 26%	126 131 -3,8%	121 129 -6,2%	144 131 10%	152 148 2,6%	146 160 -8,7%	161 154 4,4%	175	182	215	227	238
Operating income (EBITDA) M CAD	Released Forecast Spread	-3,96 -4,10 3,3%	-9,53 -4,20 -127%	-14,4 -5,57 -159%	0,21 -13,5 102%	1,04 1,04 -0,78%	1,90 1,46 30%	5,74 4,79 20%	8,56 8,18 4,6%	10,0 11,9 -16%	12,6 12,1 3,8%	18,5	23,1	32,7	36,6	40,3
Operating profit (EBIT) M CAD	Released Forecast Spread	-14,8 -14,6 -1,7%	-16,3 -10,4 -56%	-34,2 -10,1 -237%	-24,0 -25,5 6,0%	3,99 -7,25 155%	-9,56 -5,00 -91%	-12,7 -12,8 0,50%	-69,2 -6,95 -896%	20,7 -4,43 569%	-43,2 -5,08 -751%	-8,85	0,70	8,00	11,0	10,0
Pre-Tax Profit (EBT) M CAD	Released Forecast Spread				16,2 -26,5 161%	19,0 -8,35 328%	-10,0 -6,17 -62%	11,2 -13,1 186%	-101 -12,5 -706%	-3,79 -11,3 67%	-139 -12,2 -1 045%	-17,0	-12,8	1,00	4,00	4,00
Net income M CAD	Released Forecast Spread	21,2 -8,20 358%	54,8 0,15 37 304%	-108 6,77 -1 697%	15,8 -16,5 196%	16,4 -3,84 529%	-7,93 -7,43 -6,8%	5,70 -11,8 148%	-98,8 -10,2 -874%	-5,10 -9,50 46%	-121 -10,3 -1 074%	-14,3	-11,0	1,00	4,00	4,00
EPS CAD	Released Forecast Spread	0,09 -0,02 486%	0,22 -0,01 4 500%	-0,43 -0,01 -4 200%	0,05 -0,07 171%	0,07 -0,03 380%	-0,03 -0,03 -15%	0,02 -0,04 147%	-0,39 -0,04 -983%	-0,02 -0,03 40%	-0,42 -0,03 -1 192%	-0,05	-0,04		0,01	0,01
Announcement Date		10/12/2018	01/11/2019	04/15/2019	08/01/2019	10/15/2019	01/14/2020	04/15/2020	07/29/2020	10/15/2020	01/14/2021